AstraZeneca PLC (STO:AZN)
Sweden
· Delayed Price · Currency is SEK 1,389.50
-2.00 (-0.14%)
May 6, 2025, 12:00 PM CET
AstraZeneca Revenue
AstraZeneca had revenue of $13.59B USD in the quarter ending March 31, 2025, with 7.17% growth. This brings the company's revenue in the last twelve months to $54.98B, up 15.48% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$54.98B
Revenue Growth
+15.48%
P/S Ratio
3.86
Revenue / Employee
$583.05K
Employees
94,300
Market Cap
2,131.48B SEK
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.24B |
| Sectra AB | 3.30B |
| Getinge AB | 35.57B |
| Camurus AB | 1.87B |
| Medicover AB | 23.56B |
| AddLife AB | 10.42B |
| Vitrolife AB | 3.61B |
| Bonesupport Holding AB | 997.85M |
AstraZeneca News
- 3 days ago - AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma - Benzinga
- 3 days ago - AstraZeneca succeeds in late-stage trials for asthma therapy - Seeking Alpha
- 4 days ago - Alembic Pharma gets USFDA final nod for Ticagrelor 90 mg, tentative approval for 60 mg - Business Upturn
- 4 days ago - AstraZeneca's Breztri meets main goals of late-stage asthma trials - Reuters
- 6 days ago - Step up now or lose jobs to US, AstraZeneca boss Pascal Soriot warns European pharma firms - This is Money
- 6 days ago - What Does the Market Think About AstraZeneca? - Benzinga
- 6 days ago - AstraZeneca PLC (AZN) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 6 days ago - AstraZeneca discontinues Truqap trial in castration-resistant prostate cancer - Seeking Alpha